ProBio, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, today announced the opening of its flagship Cell and Gene Therapy Center of ...

Additionally, the findings suggest that future adenoviral vector-based vaccines could be modified to reduce interactions with PF4 and minimize the risk of immune-related complications.

The 128,000 sq ft GMP facility is purpose-built for manufacturing high-quality plasmid DNA and viral vectors, including adeno-associated virus (AAV) and lentiviral vector (LVV) platforms ...

Adeno-associated viruses (AAVs) have emerged as essential tools for delivering genetic material into tissues and engineering ...